These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7769297)

  • 21. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.
    Wang S; Taaffe J; Parker C; Solórzano A; Cao H; García-Sastre A; Lu S
    J Virol; 2006 Dec; 80(23):11628-37. PubMed ID: 16987975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.
    Subbotina TI; Tenkova TV; Sidorova LV; Shpilyuk GF; Drinevsky VP; Voitsekhovskaya EM; Konstantinov VK; Sominina AA
    Acta Virol; 1988 Nov; 32(6):494-502. PubMed ID: 2906221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly.
    Gorse GJ; Otto EE; Powers DC; Chambers GW; Eickhoff CS; Newman FK
    J Infect Dis; 1996 Feb; 173(2):285-90. PubMed ID: 8568287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel influenza A (H1N1) vaccine in various age groups.
    Zhu FC; Wang H; Fang HH; Yang JG; Lin XJ; Liang XF; Zhang XF; Pan HX; Meng FY; Hu YM; Liu WD; Li CG; Li W; Zhang X; Hu JM; Peng WB; Yang BP; Xi P; Wang HQ; Zheng JS
    N Engl J Med; 2009 Dec; 361(25):2414-23. PubMed ID: 19846844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.
    Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E
    Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus.
    Wesley RD; Tang M; Lager KM
    Vaccine; 2004 Sep; 22(25-26):3427-34. PubMed ID: 15308368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
    Keitel WA; Treanor JJ; El Sahly HM; Gilbert A; Meyer AL; Patriarca PA; Cox MM
    Vaccine; 2009 Dec; 28(2):379-85. PubMed ID: 19879222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of avian H5N1 influenza virus recombinant vaccines in cats.
    Uhl EW; Harvey SB; Michel F; Perozo Y; Gabbard J; Tompkins SM; Hogan RJ
    Viral Immunol; 2010 Apr; 23(2):221-6. PubMed ID: 20374002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.
    Chan CY; Tambyah PA
    Expert Rev Vaccines; 2012 Jul; 11(7):759-73. PubMed ID: 22913252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine.
    Mbawuike IN; Piedra PA; Cate TR; Couch RB
    J Med Virol; 1996 Oct; 50(2):105-11. PubMed ID: 8915874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.